A jury has ordered Medtronic to pay $382 million after finding the company liable in an antitrust case accusing it of maintaining a monopoly in the market for a surgical device, Fierce Biotech reports.

The $382 million award is the headline outcome of the litigation. The verdict marks one of the larger antitrust judgments against a major medical device manufacturer in recent years, and it lands on Medtronic, the world's largest standalone medical technology company.

What did the jury decide?

The jury found that Medtronic unlawfully monopolized the market for a surgical device. The panel awarded $382 million in damages to the plaintiffs, who accused the company of using its dominant position to shut out rivals.

Why does the verdict matter for practitioners?

Antitrust plaintiffs in the medical device sector now have a concrete data point: a nine-figure damages award against a dominant manufacturer on monopoly-maintenance theories. Defense counsel will scrutinize the verdict form and the market-definition evidence for appeal grounds, and the award is likely to encourage copycat suits by competitors and purchasers in other device categories. For Medtronic, the immediate questions are post-trial motions, potential trebling exposure under antitrust law, and whether the company sets aside reserves or discloses the liability in its next filing.

Medtronic can be expected to challenge the verdict. Until post-trial motions and any appeal resolve, the $382 million figure remains subject to reduction or reversal.

What happens next?

Key procedural milestones to watch:

• Post-trial motions by Medtronic seeking to overturn or reduce the award
• Any appeal of liability and damages findings
• Possible follow-on litigation from other plaintiffs citing the verdict

The case underscores rising antitrust enforcement risk across the medtech industry, where distribution power and bundled purchasing arrangements have drawn growing scrutiny from private plaintiffs and regulators alike.